drugset
drugset / Trial / NCT00045149

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00045149 ↗

Phase 1 Completed Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Timeline

Start
2002-10
Primary completion
—
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy — Intravenous
Background aldesleukin Protein / enzyme biologic — Subcutaneous

Indications

cutaneous melanoma